Skip to main content

A Randomized, Double-masked, Multicenter, 3-Arm Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema

Open
  • Protocol code: EYE-RES-102
  • EudraCT code: No aplica
  • Research group: Ophtalmology
  • Service: Ophthalmology
  • Principal investigator:  Garrido Marin, Marta
  • Pathology: Malalties de l’ull i dels seus annexos
  • Phase: Fase III